Company Filing History:
Years Active: 2002
Title: Milcho S. Mincheff: Innovator in Cancer Immunotherapy
Introduction
Milcho S. Mincheff is a prominent inventor based in Rockville, MD (US), known for his groundbreaking work in cancer immunotherapy. His innovative approach focuses on the expression of truncated tumor or tumor-associated antigens, which has the potential to revolutionize cancer treatment.
Latest Patents
Milcho S. Mincheff holds 1 patent for his invention titled "Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen." This patent includes DNA constructs for truncated forms of cancer-specific or cancer-associated antigens, which are incorporated into plasmid or viral expression vectors. The rationale behind using truncated constructs is to minimize side effects such as toxicity and signal transduction that may arise from full-size molecules.
Career Highlights
Mincheff's work has led to significant advancements in the treatment of metastatic prostate cancer. His innovative methods involve the injection of DNA coding for the human prostate-specific membrane antigen (XC-PSMA) using a mammalian expression vector under the CMV promoter or a replication-defective adenoviral vector (Ad5). Additionally, he has developed a technique where dendritic cells are isolated from patients and treated with the plasmid or adenovirus before being injected back into the patient. This approach has shown promise in retarding or stopping the progression of metastatic prostate cancer in some patients.
Collaborations
Milcho S. Mincheff has collaborated with notable colleagues, including Dmitri Loukinov and Serguei Zoubak, to further enhance the research and development of cancer immunotherapy techniques.
Conclusion
Milcho S. Mincheff's contributions to cancer immunotherapy through his innovative patent and collaborative efforts mark him as a significant figure in the field. His work continues to inspire advancements in cancer treatment and offers hope for patients battling this disease.